Clinical trial
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
NCT02288247 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 1, 2014
- Completion date
- March 15, 2024
- Enrollment
- 688 (actual)
- Sites
- 89
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic castration resistant prostate cancer